|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,090 DKK | -0.91% |
|
+4.11% | -18.05% |
| Mar. 27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
Orphazyme A/S reported earnings results for the half year ended June 30, 2022. For the half year, the company reported net income was DKK 62.98 million compared to net loss of DKK 463.78 million a year ago. Basic loss per share from continuing operations was DKK 0.69 compared to DKK 1.58 a year ago.
Basic earnings per share was DKK 1.79 compared to basic loss per share of DKK 13.27 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.05% | 5.51M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
ORPHAZYME A/S 
